Bottom line
Is SGPIX a good fund? The bottom line
SGPIX is a share class of Small-cap Growth Profund, an actively managed small-cap mutual fund from ProShares.
Its expense ratio is 1.78% — about $178 a year on every $10,000 invested, more expensive than 91% of small-cap funds we track.
It returned +7.6% over one year, +6.3% a year over five years, +7.6% a year over ten (as of Dec 31, 2024, per its prospectus).
With $8.4 million in net assets and 354 holdings, its largest position is Corcept Therapeutics Inc (1.3%) and the top 10 make up 10.1% of the portfolio.
The closest lower-cost alternative we found is VIOG (0.1%, 62% top-holdings overlap).
What stands out
- Broadly diversified (354 holdings)
What to watch
- Expensive for its category (1.78%)
- Small fund ($8.4 million) — small funds are likelier to close
- High turnover (120,1% a year) can mean more taxable distributions
Updated Nov 19, 2026
What SGPIX invests in
Small-Cap Growth ProFund (the Fund) seeks investment results, before fees and expenses, that track the performance of the S&P SmallCap 600 Growth Index (the Index).
The Fund invests in financial instruments that ProFund Advisors believes, in combination, should track the performance of the Index. The Index is designed to measure the performance of growth stocks included in the S&P SmallCap 600 Index. The S&P SmallCap 600 Index is designed to measure the performance of small-cap companies listed and domiciled in the U.S. As of July 31, 2025, the market capitalization of companies in the Index was between $ 262 million and $10.7 billion. The Index includes the stocks in the Small-Cap S&P 600 Index with the strongest growth characteristics based on: sales growth, earnings growth to price ratio, and momentum. The selected stocks are then weighted based on market capitalization. The Indexs composition and assigned weights are reevaluated annually in December with additional weight adjustments in March, June and September. The Index is constructed and…
From the fund's prospectus (filed Nov 25, 2025).
SGPIX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| SGPIX | +7.6% | +6.3% | +7.6% |
| Small-Cap median | +7.6% | +7.0% | +9.2% |
Source: Fund prospectus, as of Dec 31, 2024
What SGPIX costs
On a $10,000 investment, SGPIX's 1.78% expense ratio costs about $178 a year. The prospectus estimates $2,261 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.
SGPIX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Corcept Therapeutics Inc | 1.26% |
| 2 | Viasat Inc | 1.20% |
| 3 | Brinker International Inc | 1.05% |
| 4 | Ryman Hospitality Properties Inc | 0.97% |
| 5 | Formfactor Inc | 0.95% |
| 6 | Protagonist Therapeutics Inc | 0.95% |
| 7 | Esco Technologies Inc | 0.94% |
| 8 | Alkermes Plc | 0.94% |
| 9 | Stonex Group Inc | 0.93% |
| 10 | Argan Inc | 0.91% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 10.1% of the fund. See all top 25 holdings and asset mix →